Changes in Baseline PSA Levels in Japanese Men From 1988 to 2003

Urology

Volumn 72, Issue 1, 2008, Pages 95-98

  Ohi, Masaru ^a   Ito, Kazuto ^a   Yamamoto, Takumi ^a   Miyakubo, Mai ^a   Takechi, Hiroyuki ^a   Kubota, Yutaka ^a   Suzuki, Kazuhiro ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; CONTROLLED STUDY; DEATH CERTIFICATE; DISEASE COURSE; HEALTH SURVEY; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL;

AGED; HUMANS; JAPAN; MALE; MASS SCREENING; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 45849125375     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2008.03.014     Document Type: Article

References (12)

1. In: Tominaga S., Kuroishi T., and Aoki K. (Eds). Cancer Mortality Statistics in 33 Countries 1953-1992 (1998), Roppo Shupan, Nagoya
2. Number of death from malignant neoplasms by site, sex and calendar year (1970-2006). Annual Report (2006). http://www.mhlw.go.jp/toukei/saikin/hw/jinkou/suii06/deth15.html Accessed February 12, 2008 (Japanese)
3. Ito K., Yamamoto T., Takechi H., et al. Impact of exposure rate of PSA-screening on clinical stage of prostate cancer in Japan. J Urol 175 suppl (2006) 477-478
4. Parkin D.M., Whelan S.L., Ferlay J., et al. Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors, Prostate (C61). In: Parkin D.M., Whelan S.L., Ferlay J., et al. (Eds). Cancer Incidence in Five Continents vol VIII (2002), International Agency for Research on Cancer, Lyon 633-635
5. Ito K., Raaijmakers R., Roobol M., et al. Prostate carcinoma detection and increased prostate-specific antigen levels after 4 years in Dutch and Japanese males who had no evidence of disease at initial screening. Cancer 103 (2005) 242-250
6. Candas B., Labrie F., Gomez J.L., et al. Relationship among initial serum prostate specific antigen, prostate specific antigen progression and prostate cancer detection at repeat screening visits. J Urol 175 (2006) 510-516
7. McGreevy K., Rodgers K., Lipsitz S., et al. Impact of race and baseline PSA on longitudinal PSA. Int J Cancer 118 (2006) 1773-1776
8. Ito K., Yamamoto T., Ohi M., et al. Cumulative probability of PSA increase above 4.0 ng/ml in population based screening for prostate cancer. Int J Cancer 109 (2004) 455-460
9. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2007. CA Cancer J Clin 57 (2007) 43-66
10. The Population-based Cancer Registry Research Group (Chairperson: Hideaki Tsukuma). Annual report (22): age-adjusted incidence rates of malignant neoplasms by site, sex and calendar year (1975-1998). http://www.ncc.go.jp/jp/statistics/2003/data08.pdf Accessed July 27, 2004
11. Stamey T.A., Kabalin J.N., McNeal J.E., et al. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J Urol 141 (1989) 1076-1083
12. de Koning H.J., Auvinen A., Berenguer Sanchez A., et al. Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial. Int J Cancer 97 (2002) 237-244